RG6620 / Roche - LARVOL DELTA

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=410 | Recruiting | Sponsor: Genentech, Inc. | Trial completion date: Nov 2028 ➔ May 2028 | Trial primary completion date: Nov 2028 ➔ May 2028

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • KRAS

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=410 | Recruiting | Sponsor: Genentech, Inc. | Phase classification: P1/2 ➔ P1

Phase classification • Oncology • Solid Tumor • KRAS

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=410 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor • KRAS